Stocks:
5,782
ETFs:
2,400
Exchanges:
11
Market Cap:
$53.48T
24h Vol:
$9.97B
Dominance:
AAPL:5.51%
Stocklytics Platform
Instrument logo  NLSP

NLS Pharmaceutics AG

NLSP
40 / 100
$0.405.51%$0.02

Performance History

Placeholder
Key Stats
Open$0.38
Prev. Close$0.38
EPS-0.84
Dividend$0.00
Next Earnings Date-
Dividend Yield %-
Market Cap
$13.03M
PE Ratio-
lowhigh
Day Range0.38
0.45
52 Week Range0.26
1.88
Ratios
P/B Ratio
25.78
Revenue-
Operating M. %
0.00%
Earnings
-$4.32M
Earnings Growth %-
EBITDA Margin %-
ROE %
-862.92%
EPS-0.84

Score Breakdown

40vs 52. Market Avg.

All Score (40 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

NLSPMarket
Value
49
42
Quality
45
46
Ownership
17
39
Growth
19
44
Dividends-32

Financial Forecast

AI Price Prediction
line chart placeholder
Analyst Ratings
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$591.85
24H (%)0.04%
24H ($)$0.26
MARKET CAP$561.85B
PRICE$534.97
24H (%)-1.02%
24H ($)-$5.55
MARKET CAP$494.81B
PRICE$152.11
24H (%)0.31%
24H ($)$0.48
MARKET CAP$366.17B
PRICE$101.13
24H (%)0.94%
24H ($)$0.95
MARKET CAP$256.26B

About NLS Pharmaceutics AG (NLSP)

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

ISN
-
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alexander Zwyer M.B.A.
Headquarters
Zurich
Employees
0
add NLS Pharmaceutics AG to watchlist

Keep an eye on NLS Pharmaceutics AG

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.